Incyte Stock News

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Reports 2021 Fourth Quarter and Year-end Financial Results and Provides 2022 Financial Guidance and Updates on Key Clinical Programs

Incyte's (INCY) CEO Hervé Hoppenot on Q4 2021 Results - Earnings Call Transcript

Companies Reporting Before The Bell Pfizer (NYSE: PFE ) is likely to report quarterly earnings at $0.87 per share on revenue of $24.20 billion. Karyopharm Therapeutics (NASDAQ: KPTI ) is likely to report quarterly loss at $0.49 per share on revenue of $50.49 million. Thomson Reuters (NYSE: TRI ) is estimated to report quarterly earnings at $0.46 per share on revenue of $1.68 billion. Beasley Broadcast Group (NASDAQ: BBGI ) is likely to report quarterly earnings at $0.03 per share on revenue of $69.67 million. Willis Towers Watson (NASDAQ: WTW ) is projected to report quarterly earnings at $4.98 per share on revenue of $2.50 billion. Cenovus Energy (NYSE: CVE ) is expected to report quarterly earnings at $0.39 per share on revenue of $11.25 billion. Jacobs Engineering Group (NYSE: J ) is projected to report quarterly earnings at $1.58 per share on revenue of $3.51 billion. CTS (NYSE: CTS ) is estimated to report quarterly earnings at $0.47 per share on revenue of $122.96 million.

The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 867 13F filings that hedge funds and well-known value investors are required to file by the SEC.

Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double

Jakafi sales are likely to have driven Incyte's (INCY) top-line in the fourth quarter.

Sierra Oncology's Strong Data In Myelofibrosis Challenges MorphoSys And Incyte

Eli Lilly (LLY) and Incyte (INCY) said the phase 3 development program for Olumiant (baricitinib) in lupus was being discontinued and that the application seeking approval of Olumiant

Try your hand at morphing science and business for a great investment opportunity in biotech.

Incyte: Still Has Room To Grow

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte to Report Fourth Quarter and Year-End 2021 Financial Results

Stocks Analysis by Zacks Investment Research covering: Eli Lilly and Company, Pfizer Inc, Incyte Corporation, AbbVie Inc. Read Zacks Investment Research''s latest article on Investing.com

The company is gradually moving away from the concentration of revenue on sales of Jakafi. The biggest revenue driver is the start of Opzelura's sales.

On CNBCs "Mad Money Lightning Round," Jim Cramer said Incyte Corporation (NASDAQ: INCY ) "actually makes